Clinical Trial

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2019-06-03; most recent amendment 2026-01-13.
Status change: Recruiting → Active, Not Recruiting 2024-05-14
Status change: Not Yet Recruiting → Recruiting 2019-07-21
Trial Details
NCT Number NCT03974022
Lead Sponsor Dizal Pharmaceuticals
Conditions Non-Small Cell Lung Cancer
Enrollment 315 participants
Start Date 2019-07-09
Primary Completion 2024-07-29 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-29